Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure

نویسندگان

  • Lisa C Costello-Boerrigter
  • John A Schirger
  • Wayne L Miller
  • Guido Boerrigter
  • Horng H Chen
  • Ruth Kempf
  • Candace Y Lee
  • John C Burnett
چکیده

Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure Lisa C Costello-Boerrigter, John A Schirger, Wayne L Miller, Guido Boerrigter, Horng H Chen, Ruth Kempf, Candace Y Lee, John C Burnett Jr

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CD-NP: A Novel Engineered Dual Guanylyl Cyclase Activator with Anti-Fibrotic Actions in the Heart

Natriuretic peptides (NPs) are cardioprotective through the activation of guanylyl cyclase (GC) receptors A and B. CD-NP, also known as cenderitide, is a novel engineered NP that was designed to uniquely serve as a first-in-class dual GC receptor agonist. Recognizing the aldosterone suppressing actions of GC-A activation and the potent inhibitory actions on collagen synthesis and fibroblast pro...

متن کامل

The novel dual GC-A and GC-B designer natriuretic peptide, cenderitide (CD-NP), enhances the renal actions of furosemide in a model of severe heart failure

Background Patients with congestive heart failure (HF) have symptomatic improvement with diuretic therapy, although with time diuretic resistance and renal dysfunction can occur. Cenderitide (also known as CD-NP), now in clinical trials in patients with HF, is a Mayo designed chimeric natriuretic peptide which, unlike the native natriuretic peptides (NPs) ANP, BNP and CNP, binds both to guanyly...

متن کامل

Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions.

AIMS Cenderitide is a novel dual natriuretic peptide (NP) receptor chimeric peptide activator, which targets the particulate guanylyl cyclase B (pGC-B) receptor and pGC-A unlike native NPs. Cenderitide was engineered to retain the anti-fibrotic properties of C-type natriuretic peptide (CNP)/pGC-B with renal-enhancing actions facilitated by fusion to the carboxyl terminus of Dendroaspis NP (DNP)...

متن کامل

Cenderitide, a novel dual GC-A and GC-B receptor activator, is a potent chronic cardiorenal fibroinhibiting peptide which suppresses aldosterone and reduces proteinuria in models of ardiorenal fibrosis

Background Cenderitide, also known as CD-NP, is a novel Mayo engineered designer natriuretic peptide (NP), which unlike native ANP, BNP and CNP co-activates both the guanylyl (GC)-A receptor to which ANP and BNP bind and GC-B to which CNP binds. Recognizing the aldosterone suppressing actions of GC-A activation and the potent inhibition of collagen synthesis and proliferation on fibroblasts to ...

متن کامل

Bioavailability of intravenous versus subcutaneous administration of the dual GC-A and GC-B designer natriuretic peptide cenderitide in healthy canines

Background Heart failure (HF) remains a therapeutic challenge with high morbidity and mortality and frequent hospitalizations. Activators of guanylyl cyclase (GC) A and/or GCB such as naturally occurring or designer natriuretic peptides (NPs) are promising candidates for chronic drug therapy; however, parenteral administration is required. Pumps or subcutaneous administration similar to those u...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 11  شماره 

صفحات  -

تاریخ انتشار 2011